A range of ROS1/ALK TKIs have been approved for the treatment of patients with ROS1-fusion NSCLC, such as crizotinib, but compared to it, iruplinalkib is less likely to cause liver function abnormalities and diarrhea (11), which is undoubtedly a satisfactory result. Here, ALK is linked to non-small cell lung carcinoma.